Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Share-based Compensation (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Share-based Compensation for 4 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 76.07% to $1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a 51.87% decrease, with the full-year FY2025 number at $2.6 million, down 51.87% from a year prior.
  • Share-based Compensation was $1.7 million for Q4 2025 at Spruce Biosciences, up from $415000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.7 million in Q4 2025 to a low of -$77000.0 in Q2 2025.
  • A 4-year average of $1.0 million and a median of $1.1 million in 2023 define the central range for Share-based Compensation.
  • Biggest YoY gain for Share-based Compensation was 76.07% in 2025; the steepest drop was 104.57% in 2025.
  • Spruce Biosciences' Share-based Compensation stood at $802000.0 in 2022, then soared by 52.24% to $1.2 million in 2023, then decreased by 21.29% to $961000.0 in 2024, then skyrocketed by 76.07% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Share-based Compensation are $1.7 million (Q4 2025), $415000.0 (Q3 2025), and -$77000.0 (Q2 2025).